Company intelligence / Profile preview

Daiichi Sankyo Co., Ltd.

Tokyo, Tokyo-to, Japandaiichisankyo.com.br ↗

Ownership: Public · 4568
Development stage: Commercial

Overview

Daiichi Sankyo has multiple approved drugs including Enhertu (fam-trastuzumab deruxtecan) for breast cancer and recently approved Datroway (datopotamab deruxtecan) for HR-positive, HER2-negative breast cancer. The company has a robust pipeline with 8 registration trial readouts expected in 2025[10].

Therapeutic areas: CardiovascularMetabolic DisordersImmunologyDermatologyOncologyRare DiseasesNeurologyInfectious Diseases
Modalities: Antibody-drug conjugates (ADCs)small molecules
Industry: Pharma

Drug pipeline

159 assets

prasugrel or ticagrelor

Approved

158 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca (for Enhertu and Datroway)Eli Lilly & Company (for Effient)Wayfinder Biosciences (2025)Nosis Biosciences (2025)Terumo Vietnam (2025)

Beyond the preview

Go deeper on Daiichi Sankyo Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daiichi Sankyo Co., Ltd..

Explore the full profile